Howard Hughes Medical Institute’s Bristol-Myers Squibb BMY Stock Holding History

Howard Hughes Medical Institute’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-438	Closed	-$23.6K	–	91
2025 Q4	$23.6K	Hold	438	–	–	0.01%	100
2025 Q3	$19.8K	Hold	438	–	–	0.01%	117
2025 Q2	$20.3K	Buy	+438	New	+$21.5K	0.01%	109

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Howard Hughes Medical Institute's BMY Position: Q1 2026 in Review

Howard Hughes Medical Institute sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 438 shares — an estimated $23.6K sold.

Howard Hughes Medical Institute first reported a position in BMY in Q2 2025 and held it in 3 quarters. The position peaked at $23.6K in Q4 2025. 2,526 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Howard Hughes Medical Institute reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
Howard Hughes Medical Institute sold 438 Bristol-Myers Squibb shares in Q1 2026, an estimated $23.6K.
Howard Hughes Medical Institute first reported a position in Bristol-Myers Squibb in Q2 2025 and held it in 3 quarters.
Howard Hughes Medical Institute's Bristol-Myers Squibb position peaked at $23.6K in Q4 2025.
2,526 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Howard Hughes Medical Institute's 13F filing for Q1 2026, filed 15 May 2026.